APLT:NSD-Applied Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 19.77

Change

-0.10 (-0.50)%

Market Cap

USD 0.45B

Volume

0.11M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Company Website : http://www.appliedtherapeutics.com

Address : 545 Fifth Avenue, New York, NY, United States, 10017

Employees : 18

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 57.39

Short Ratio : 9.79

52 Week Low : 9.76

Shorted Shares : 1,506,320

200 Day Moving Average : 33.47

Shorted Shares Previous Month : 1,510,809

50 Day Moving Average : 24.57

Shares Held By Insiders : 233.27%

Short Percentage : 7.00%

Shares Held by Institutions : 39.85%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

 USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

 USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

 USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

 USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

 USD18.93B 47.64 35.20

ETFs Containing APLT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -27.53% 30% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.53% 30% F 29% F
Trailing 12 Months  
Capital Gain 79.89% 75% C 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.89% 75% C 87% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 67.63% N/A N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.63% N/A N/A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 123.62% N/A N/A 7% F
Risk Adjusted Return 54.71% N/A N/A 74% C
Market Capitalization 0.45B 62% D- 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.35 57% F 37% F
Price / Cash Flow Ratio -12.28 72% C- 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -80.81% 41% F 16% F
Return on Invested Capital -188.26% 10% F 4% F
Return on Assets -44.19% 22% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.08 30% F 18% F
Short Percent 11.04% 29% F 20% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector